Objetivo ULTRA-DD (Unrestricted Leveraging of Targets for Research Advancement and Drug Discovery) will be an European-wide, highly collaborative and inclusive consortium, to validate new targets for drug discovery by (1) generating high quality research tools, with an emphasis on chemical probes; (2) generating the chemical probes in the most cost-effective manner, using structure-guided methods and harnessing the chemical libraries and medicinal chemistry skills of the EFPIA participants; (3) testing the chemical probes in models of human disease based on continuous access to cells from patients with selected inflammatory diseases; and (4) making all reagents and knowledge available to the research community without restriction on use, to expand the impact well beyond the ULTRA-DD partners. In addition to our focus on chemical probes, we will also generate a defined set of antibodies targeting extracellular and membrane bound proteins of relevance to disease. To accomplish the above, ULTRA-DD will create two scientific Cores and formalize a collaborative network of SMEs, academic scientists and clinicians. The Protein Characterization and Tool-Generation Core will comprise four integrated laboratories: University of Oxford’s Structural Genomics Consortium laboratory, led by Chas Bountra (OXF-SGC), ETH in Zurich (ETHZ), led by Ruedi Aebersold, Karolinska Institutet (KI-MBB), led by Susanne Gräslund, and the University of Toronto’s SGC laboratory (UTOR-SGC, will not receive IMI funds), led by Cheryl Arrowsmith, and chemical biology teams in Bayer (Bayer), Janssen (JPNV), Novartis (NOV) and Pfizer (Pfizer). The Clinical Immunology Core will generate high quality assays from patient-derived cells and tissues in selected inflammatory diseases, and test effects of the chemical and antibody probes. This Core comprises the Kennedy Institute (UOXF-KENN) in the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences at the University of Oxford (UOXF-NDORMS), led by Marc Feldmann, the Centre for Molecular Medicine (KI-CMM) at Karolinska Institutet, led by Lars Klareskog and Per-Johan Jakobsson, and DiscoveRx (DRX, Sanj Kumar), an SME based in Birmingham, UK (will not receive IMI funds). The activities within the Cores will be enhanced significantly and the impact of the output expanded dramatically through the involvement of a Collaborative Network of SMEs, IMI projects, academic scientists and Disease Foundations (Appendices 1-3; none of these networks will receive IMI funds). The network will include a Target Prioritization Network (TPN) of top genomicists and clinicians; a Science and Technology Network (STN) that contributes expertise across the ULTRA-DD “gene to chemical probe” pipeline; and an Inflammatory Disease Network (IDN) of clinicians and translational scientists that provides enhanced access to disease-relevant expertise and patient tissue, as well as an expanded array of innovative assays. Each member of the ULTRA-DD network will commit to the open access policy. ULTRA-DD will be managed by the SGC (London, UK), which is a charitable company that has an enviable track record in managing the scientific, legal and financial aspects of open access public-private partnerships. The vision of ULTRA-DD is to create an open access consortium that provides industry with a stream of high quality target-disease associations and tools to study them. Our aspiration is to provide the evidence that convinces industry to launch >10 novel proprietary drug discovery programs based on ULTRA-DD open access output during the course of the project and in the nearest years following completion (2020).ULTRA-DD will meet the deliverables by integrating teams of tool-generating scientists with expert clinicians with access to patient tissue, under an open access, milestone-driven framework, and will expand its output through organized collaborations with innovative European scientists, leading non-European scientists Ámbito científico medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health sciencesclinical medicinerheumatologymedical and health scienceshealth sciencesinflammatory diseasesmedical and health sciencesbasic medicinemedicinal chemistrymedical and health sciencesclinical medicineorthopaedics Programa(s) FP7-JTI - Specific Programme "Cooperation": Joint Technology Initiatives Tema(s) IMI-JU-11-2013-05 - Generation Of Research Tools To Enable The Translation Of Genomic Discoveries Into Drug Discovery Projects Convocatoria de propuestas IMI-JU-11-2013 Consulte otros proyectos de esta convocatoria Régimen de financiación JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI) Coordinador NOVARTIS PHARMA AG Aportación de la UE Sin datos Dirección LICHTSTRASSE 35 4056 Basel Suiza Ver en el mapa Región Schweiz/Suisse/Svizzera Nordwestschweiz Basel-Stadt Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Investigador principal Nils Ostermann (Dr) Contacto administrativo Stephan Korte (Dr) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos Participantes (9) Ordenar alfabéticamente Ordenar por aportación de la UE Ampliar todo Contraer todo STRUCTURAL GENOMICS CONSORTIUM LBG Reino Unido Aportación de la UE € 1 353 696,00 Dirección EUSTON ROAD 215 NW1 2BE London Ver en el mapa Región London Inner London — West Camden and City of London Tipo de actividad Research Organisations Contacto administrativo Paul Van Damme (Mr.) Enlaces Contactar con la organización Opens in new window Coste total Sin datos BAYER AKTIENGESELLSCHAFT Alemania Aportación de la UE Sin datos Dirección KAISER-WILHELM-ALLEE 1 51373 Leverkusen Ver en el mapa Región Nordrhein-Westfalen Köln Leverkusen, Kreisfreie Stadt Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Contacto administrativo Petra Freitag (Mrs) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos DiscoveRx Corp Ltd Reino Unido Aportación de la UE Sin datos Dirección Faraday Wharf, Innovation Birmingham Campus, Holt Street, Birmingham Science Park Aston B7 4BB Birmingham Ver en el mapa Contacto administrativo Richard Price (Mr) Enlaces Contactar con la organización Opens in new window Coste total Sin datos EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH Suiza Aportación de la UE € 1 440 970,00 Dirección Raemistrasse 101 8092 Zuerich Ver en el mapa Región Schweiz/Suisse/Svizzera Zürich Zürich Tipo de actividad Higher or Secondary Education Establishments Contacto administrativo Martin Pestalozzi (Mr.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos JANSSEN PHARMACEUTICA NV Bélgica Aportación de la UE Sin datos Dirección TURNHOUTSEWEG 30 2340 Beerse Ver en el mapa Región Vlaams Gewest Prov. Antwerpen Arr. Turnhout Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Contacto administrativo Henk Sipma (Mr) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos KAROLINSKA INSTITUTET Suecia Aportación de la UE € 4 902 660,00 Dirección Nobels Vag 5 17177 Stockholm Ver en el mapa Región Östra Sverige Stockholm Stockholms län Tipo de actividad Higher or Secondary Education Establishments Contacto administrativo Caroline HAMILTON (Ms.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD Reino Unido Aportación de la UE € 13 502 674,00 Dirección WELLINGTON SQUARE UNIVERSITY OFFICES OX1 2JD Oxford Ver en el mapa Región South East (England) Berkshire, Buckinghamshire and Oxfordshire Oxfordshire Tipo de actividad Higher or Secondary Education Establishments Contacto administrativo Gill Wells (Ms) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos PFIZER LIMITED Reino Unido Aportación de la UE Sin datos Dirección RAMSGATE ROAD CT13 9NJ Sandwich Ver en el mapa Región South East (England) Kent East Kent Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Contacto administrativo Carla Cox (Dr) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO Canadá Aportación de la UE Sin datos Dirección KINGS COLLEGE CIRCLE 27 M5S 1A1 Toronto Ver en el mapa Tipo de actividad Higher or Secondary Education Establishments Contacto administrativo Arij Al Chawaf (Dr.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos